Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Bilirubin Glucuronide

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    15 result(s) found for: Bilirubin Glucuronide. Displaying page 1 of 1.
    EudraCT Number: 2010-019678-34 Sponsor Protocol Number: not applicable Start Date*: 2011-07-29
    Sponsor Name:
    Full Title: Paracetamol intravenously in neonates with a gestational age of less than 32 weeks
    Medical condition: Neonatal pain
    Disease:
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-001762-13 Sponsor Protocol Number: 747-401 Start Date*: 2018-08-01
    Sponsor Name:Intercept Pharmaceuticals, Inc.
    Full Title: A Phase 4, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Pharmacokinetics and Safety of Obeticholic Acid in Patients with Primary Biliary Cholangitis and Moderate to Severe Hepa...
    Medical condition: Primary Biliary Cholangitis and Moderate to Severe Hepatic Impairment
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) DE (Prematurely Ended) BE (Completed) HU (Prematurely Ended) EE (Prematurely Ended) LT (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-002295-40 Sponsor Protocol Number: 08-06-2018-paracet Start Date*: 2018-09-11
    Sponsor Name:Copenhagen Neuromuscular Center
    Full Title: Pharmacokinetics and safety of treatment with paracetamol in children and adults with spinal muscular atrophy and cerebral palsy
    Medical condition: Spinal muscular atrophy type II (SMA II) Cerebral palsy (CP)
    Disease:
    Population Age: Children, Under 18, Adults Gender: Male, Female
    Trial protocol: DK (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-005006-62 Sponsor Protocol Number: ASZ-001 Start Date*: 2019-12-10
    Sponsor Name:Albert Schweitzer hospital
    Full Title: Pharmacokinetics of Paracetamol before and after Roux-en-Y gastric bypass
    Medical condition: Roux-en-Y gastric bypass
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004848 10033762 Paracetamol LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-002392-35 Sponsor Protocol Number: KRT-232-113 Start Date*: 2021-02-05
    Sponsor Name:Kartos Therapeutics, Inc.
    Full Title: An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 with TL-895 in Subjects with Relapsed/Refractory Myelofibrosis and of KRT-232 in Janus-associated Kinase Inhibitor...
    Medical condition: Relapsed/Refractory Myelofibrosis and Janus-associated Kinase Inhibitor-Intolerant Myelofibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028537 Myelofibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) HU (Prematurely Ended) PL (Prematurely Ended) DE (Prematurely Ended) AT (Prematurely Ended) BG (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-003109-73 Sponsor Protocol Number: TL-895-203 Start Date*: 2021-02-15
    Sponsor Name:Telios Pharma, Inc.
    Full Title: An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of TL-895 Combined with KRT-232 in Subjects with Relapsed/Refractory (R/R) FLT3+ Acute Myeloid Leukemia (AML)
    Medical condition: Relapsed/Refractory (R/R) FLT3+ Acute Myeloid Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10081514 Acute myeloid leukemia refractory LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Prematurely Ended) AT (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-002464-31 Sponsor Protocol Number: KRT-232-111 Start Date*: 2021-02-12
    Sponsor Name:Kartos Therapeutics Inc.
    Full Title: An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 in Combination with Acalabrutinib in Subjects with Relapsed/Refractory Diffuse Large B-cell Lymphoma or Relapsed/R...
    Medical condition: - Relapsed/Refractory (R/R) de novo TP53 ABC (non-GCB) or GCB diffuse large B-cell lymphoma (DLBCL) - R/R TP53 chronic lymphocytic leukemia (CLL) naïve to prior Bruton's tyrosine kinase (BTK) inhib...
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012822 Diffuse large B-cell lymphoma refractory PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012821 Diffuse large B-cell lymphoma recurrent PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008976 Chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) CZ (Completed) PT (Ongoing) FR (Ongoing) BE (Completed) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-011925-14 Sponsor Protocol Number: 1199.37 Start Date*: 2009-08-24
    Sponsor Name:Boehringer Ingelheim
    Full Title: A multicenter, open label, phase I / II study to evaluate safety, pharmacokinetics and efficacy of BIBF 1120 in comparison with oral sorafenib for advanced hepatocellular carcinoma patients.
    Medical condition: Histologically or cytologically confirmed hepatocellular carcinoma not amenable to local therapy with adequate renal, hematological and liver paramenters with Child-Pugh score 7 or less, in 1st lin...
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10049010 Carcinoma hepatocellular LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) AT (Completed) DE (Completed) SK (Completed) HU (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2019-001201-24 Sponsor Protocol Number: KRT-232-104 Start Date*: 2019-12-02
    Sponsor Name:Kartos Therapeutics, Inc.
    Full Title: An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined with Low-Dose Cytarabine (LDAC) or Decitabine in Patients with Acute Myeloid Leukemia (AML).
    Medical condition: Relapsed or refractory AML, AML secondary to myeloproliferative neoplasms (MPN), and JAK2 mutationpositive AML.
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) DE (Completed) GB (GB - no longer in EU/EEA) BE (Prematurely Ended) HU (Completed) PL (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-002724-25 Sponsor Protocol Number: 08-2018-07-31 Start Date*: 2017-11-16
    Sponsor Name:Helle Holst
    Full Title: Intravenous and oral paracetamol in neonates: safety and ethanol-drug interactions – the PARASHUTE Trial
    Medical condition: Liver toxicity following prolonged administration of i.v. or oral paracetamol
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004871 10019850 Hepatotoxic effect LLT
    Population Age: Preterm newborn infants, Newborns, Under 18 Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-004699-16 Sponsor Protocol Number: KRT-232-117 Start Date*: 2021-03-15
    Sponsor Name:Kartos Therapeutics, Inc.
    Full Title: An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined with a Tyrosine Kinase Inhibitor (TKI) in Patients with Relapsed or Refractory Ph+ Chronic Myeloid Leukem...
    Medical condition: Phase 1b and Phase 2 Arms A and B: Adults with tumor protein 53 wild type (TP53wt) Philadelphia chromosome positive (Ph+) CML in chronic phase who are refractory or intolerant to ≥ 2 prior TKIs and...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10009015 Chronic myeloid leukemia LLT
    21.0 100000004864 10054352 Chronic phase chronic myeloid leukemia LLT
    22.0 100000004864 10082178 Philadelphia positive chronic myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) HU (Prematurely Ended) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-010572-20 Sponsor Protocol Number: CA198-002 Start Date*: 2009-10-12
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 1/2 Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-863233 in Subjects with Advanced and/or Metastatic Solid Tumors
    Medical condition: Advanced and/or metastatic solid tumors
    Disease: Version SOC Term Classification Code Term Level
    9.1 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2015-001012-35 Sponsor Protocol Number: G200802 Start Date*: 2015-10-06
    Sponsor Name:GTx, Inc.
    Full Title: A Phase 2 Open Label, Multi-Center, Multinational, Randomized, Parallel Design Study Investigating The Efficacy and Safety Of GTx-024 On Metastatic or Locally Advanced ER+/AR+ Breast Cancer (BC) in...
    Medical condition: Estrogen Receptor Positive and Androgen Receptor Positive Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070575 Estrogen receptor positive breast cancer LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10072740 Locally advanced breast cancer LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070577 Oestrogen receptor positive breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BG (Prematurely Ended) HU (Ongoing) LT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-001530-19 Sponsor Protocol Number: KRT-232-112 Start Date*: 2021-10-27
    Sponsor Name:Kartos Therapeutics, Inc.
    Full Title: An Open-Label, Multicenter, Phase 2 Study of the Safety and Efficacy of KRT-232 in Subjects with Relapsed or Refractory Small Cell Lung Cancer (SCLC)
    Medical condition: Subjects with Relapsed or Refractory Small Cell Lung Cancer (SCLC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025044 Lung cancer LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041067 Small cell lung cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041070 Small cell lung cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) DE (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2014-004989-23 Sponsor Protocol Number: G200901 Start Date*: 2015-08-20
    Sponsor Name:GTx, Inc.
    Full Title: A Phase 2 Open Label, Multi-Center, Multinational Study Investigating The Efficacy and Safety Of GTx-024 On Advanced, Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)
    Medical condition: Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10072737 Advanced breast cancer LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006198 Breast cancer recurrent PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: LT (Completed) GB (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 21:11:46 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA